EUVIMEDEUVIMED entdecken
Multizentrische Studie

Reduced doses of emicizumab achieve good efficacy: Results from a national‐wide multicentre real‐world study in China

Yuan Xu iD, Ying Wang, Runhui Wu iD, Changcheng Zheng, Li Zhang, Weiqun Xu, Xiaoqin Feng, Hua Wang, Xiangshan Cao, Liya He, Tianyang Xue, Mingwei Jin und 11 weitere

Haemophilia · 2024

DOI: 10.1111/hae.15062 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Haemophilia, 2024. Verfasst von Yuan Xu und 22 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute …. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Antibodies, Monoclonal, Humanized, Hemophilia A. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: CAMS Innovation Fund for Medical Sciences, National Key Research and Development Program of China, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Reduced doses of emicizumab improve the affordability among patients in developing countries. However, the relationship between variant dose selection and efficacy in the real world of China is still unclear.

Aim

This study aimed to investigate the efficacy and safety of emicizumab especially in those on reduced dose regimens in a real‐world setting.

Methods

We carried out a multicentre study from 28 hospitals between June 2019 and June 2023 in China and retrospectively analysed the characteristics including demographics, diagnosis, treatment, bleeding episodes, and surgical procedures.

Results

In total, 127 patients with haemophilia A, including 42 with inhibitors, were followed for a median duration of 16.0 (IQR: 9.0–30.0) months. Median age at emicizumab initiation was 2.0 (IQR: 1.0–4.0) years. Median (IQR) consumption for loading and maintenance was 12.0 (8.0–12.0) and 4.2 (3.0–6.0) mg/kg/4 weeks, respectively. While on emicizumab, 67 (52.8%) patients had no bleeds, whereas 60 (47.2%) patients had any bleeds, including 26 with treated bleeds. Compared to previous treatments, patients on emicizumab had significantly decreased annualized bleeding rate, annualized joint bleeding rate, target joints and intracerebral haemorrhage. Different dosages had similar efficacy except the proportion of patients with treated spontaneous bleeds and target joints. Adverse events were reported in 12 (9.4%) patients. Postoperative excessive bleeding occurred following two of nine procedures.

Conclusion

This is the largest study describing patients with HA receiving emicizumab prophylaxis on variant dose regimens in China. We confirmed that nonstandard dose is efficacious and can be considered where full‐dose emicizumab is ill affordable.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, BispecificAntibodies, Monoclonal, HumanizedHemophilia AHumansChinaMaleRetrospective StudiesChild, PreschoolFemaleTreatment OutcomeInfantHemorrhageChildDose-Response Relationship, Drug

Stichwörter der Autor:innen

Chinableedingemicizumabfactor VIIIhaemophilia Aprophylaxis

Substanzen

emicizumabAntibodies, BispecificAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sc…
  • Tianjin Institutes of Health Science, Tianjin, China.
  • Department of Hematology and Oncology, Shenzhen Children's Hospital, Shenzhen, China.
  • Hematology Oncology Center, National Center for Children's Health, Beijing Children's Hospital, Capital Medical University, Beijing, China.
  • Department of Hematology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
  • Department of Hematology, Children's Hospital of Chongqing Medical University, Chongqing, China.

ORCID-Profile: Yuan Xu, Runhui Wu, Man-Chiu Poon, Wei Liu, Feng Xue

Förderung

  • CAMS Innovation Fund for Medical Sciences
  • National Key Research and Development Program of China
  • National Natural Science Foundation of China

Zitieren

APA

Xu, Y., Wang, Y., Wu, R., Zheng, C., Zhang, L., Xu, W., Feng, X., Wang, H., Cao, X., He, L., Xue, T., Jin, M., Xie, B., Ling, J., Sun, L., Su, R., Cheng, H., Fang, Y., Poon, M. C., …, & Yang, R. (2024). Reduced doses of emicizumab achieve good efficacy: Results from a national‐wide multicentre real‐world study in China. Haemophilia. https://doi.org/10.1111/hae.15062

Vancouver

Xu Y, Wang Y, Wu R, Zheng C, Zhang L, Xu W, et al. Reduced doses of emicizumab achieve good efficacy: Results from a national‐wide multicentre real‐world study in China. Haemophilia. 2024. doi:10.1111/hae.15062

BibTeX
@article{Xu2024,
  author = {Xu, Yuan and Wang, Ying and Wu, Runhui and Zheng, Changcheng and Zhang, Li and Xu, Weiqun and Feng, Xiaoqin and Wang, Hua and Cao, Xiangshan and He, Liya and Xue, Tianyang and Jin, Mingwei and Xie, Bingshou and Ling, Jing and Sun, Lirong and Su, Rui and Cheng, Hongbo and Fang, Yongjun and Poon, Man-Chiu and Liu, Wei and Zhang, Lei and Xue, Feng and Yang, Renchi},
  title = {Reduced doses of emicizumab achieve good efficacy: Results from a national‐wide multicentre real‐world study in China},
  journal = {Haemophilia},
  year = {2024},
  doi = {10.1111/hae.15062}
}
Kostenlos starten →